Pfizer exercises right to develop Cytos's vaccines
This article was originally published in Scrip
Pfizerhas exercised its option to acquire commercial licences for specific vaccines from Cytos Biotechnology. The vaccines, based on the Swiss company's Immunodrug technology, target specific diseases outside Cytos's own R&D programmes. It retains the rights to develop, manufacture and commercialise vaccines against different disease targets for the same human diseases. Pfizer will pay Cytos for the exclusive global rights to develop, manufacture and commercialise the vaccines. Immunodrugs are a new class of biopharmaceuticals that use virus-like particles, recombinantly produced virus shells containing no viral genetic information, as carriers for a variety of antigens to elicit a targeted immune response. Pfizer and Cytos signed an initial research, option and licence agreement in August last year (Scrip Online, August 15th, 2008).
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.